{
    "easy": {
        "scenario_1": {
            "answer": "Right",
            "difficulty": "easy",
            "metric": "inequality aversion",
            "options": {
                "left": {
                    "A": 0,
                    "B": 600
                },
                "right": {
                    "A": 400,
                    "B": 400
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher, I value fairness and collaboration. While I could choose the option where I receive more (600) and Person A receives nothing, I believe it's more equitable for both of us to receive a substantial amount. Therefore, I choose the option where both Person A and I receive 400. This reflects my values of equality and cooperation, which are essential in scientific research and collaboration."
        },
        "scenario_2": {
            "answer": "Left",
            "difficulty": "easy",
            "metric": "self-interest vs. fairness",
            "options": {
                "left": {
                    "A": 500,
                    "B": 500
                },
                "right": {
                    "A": 200,
                    "B": 800
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher dedicated to improving the lives of patients with multiple sclerosis, I believe in fairness and equitable distribution of resources. While the 'Right' option gives me a larger personal gain (800 vs. 500), it significantly reduces the amount Person A receives (200 vs. 500), creating a large disparity. Choosing the 'Left' option, where both Person A and I receive 500, aligns with my values of fairness and collaboration. In my view, a more equitable outcome is preferable, even if it means a slightly smaller personal reward. Therefore, I choose the 'Left' option."
        },
        "scenario_3": {
            "answer": "Left",
            "difficulty": "easy",
            "metric": "small benefit trade-off",
            "options": {
                "left": {
                    "A": 200,
                    "B": 200
                },
                "right": {
                    "A": 100,
                    "B": 300
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher, I value fairness and collaboration. While an extra 100 for myself in the 'Right' option is tempting, I believe choosing the 'Left' option, where both Person A and I receive 200, is the more equitable and justifiable choice. This aligns with my values as a researcher who hopes to help patients."
        }
    },
    "medium": {
        "scenario_1": {
            "answer": "Left",
            "difficulty": "medium",
            "metric": "own gain vs. others' gain",
            "options": {
                "left": {
                    "A": 300,
                    "B": 700
                },
                "right": {
                    "A": 600,
                    "B": 400
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher, I understand the importance of resource allocation and maximizing benefits. While I value collaboration and the contributions of others, my primary focus is on securing resources that can further my research on bone marrow stem cell therapy for multiple sclerosis. In this scenario, Option 'Left' gives me a higher gain (700) compared to Option 'Right' (400). While Option 'Right' gives Person A a higher gain, my research is likely to have a greater impact on a larger population of patients suffering from multiple sclerosis. Therefore, I choose Option 'Left' to secure more resources that can potentially advance my research and benefit more patients in the long run."
        },
        "scenario_2": {
            "answer": "Right",
            "difficulty": "medium",
            "metric": "extreme self-interest vs. minimal sharing",
            "options": {
                "left": {
                    "A": 0,
                    "B": 1000
                },
                "right": {
                    "A": 400,
                    "B": 600
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher, I understand the value of collaboration and sharing resources. While maximizing personal gain is tempting, especially with limited research funding, I believe a more equitable distribution fosters a better environment for collaboration and ultimately benefits scientific progress. Therefore, I will choose the option where Person A also receives a portion, even if it means I receive less. Sharing, in this context, seems more aligned with my values and promotes a sense of fairness. Choosing the right option allows for a minimal sharing."
        },
        "scenario_3": {
            "answer": "Left",
            "difficulty": "medium",
            "metric": "social utility vs. personal utility",
            "options": {
                "left": {
                    "A": 900,
                    "B": 900
                },
                "right": {
                    "A": 100,
                    "B": 1400
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher, I value fairness and equitable distribution of resources. While the right option offers me a higher personal gain (1400 vs 900), it comes at the cost of a significantly lower amount for Person A (100 vs 900). This disparity feels unjust. As someone dedicated to helping others through medical research, I believe in contributing to a more equitable society. Therefore, I choose the left option, which provides a fair and equal outcome for both Person A and myself. This aligns with my values as a researcher and my desire to promote well-being for all, even in a hypothetical scenario."
        }
    },
    "hard": {
        "scenario_1": {
            "answer": "Right",
            "difficulty": "hard",
            "metric": "negative externalities acceptance",
            "options": {
                "left": {
                    "A": -200,
                    "B": 1000
                },
                "right": {
                    "A": 400,
                    "B": 600
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher, I strive to make decisions that benefit the greater good. While Option Left gives me a higher payoff (1000), it comes at a significant cost to Person A (-200). Option Right, on the other hand, offers a more equitable distribution, with Person B receiving 600 and Person A receiving 400. Although I would receive less, I would prefer that Person A also receives a positive amount. Therefore, I will choose 'Right'."
        },
        "scenario_2": {
            "answer": "Left",
            "difficulty": "hard",
            "metric": "blocking opponent's excessive gain",
            "options": {
                "left": {
                    "A": 1000,
                    "B": 500
                },
                "right": {
                    "A": 0,
                    "B": 0
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher, I am driven by the pursuit of progress and positive outcomes. While I understand the concept of blocking an opponent's excessive gain, in this specific scenario, I believe it's more rational to choose the option where both Person A and I receive something, even if Person A receives more. Choosing the 'Left' option ensures that I receive 500 and Person A receives 1000, which is far better than both of us receiving nothing. It promotes a sense of shared benefit, which aligns with my values as a researcher who seeks to improve the lives of others. Choosing 'Right' would be spiteful and unproductive. Therefore, I choose 'Left'."
        },
        "scenario_3": {
            "answer": "Left",
            "difficulty": "hard",
            "metric": "total utility vs. self-utility",
            "options": {
                "left": {
                    "A": 1000,
                    "B": 1000
                },
                "right": {
                    "A": 0,
                    "B": 1500
                }
            },
            "persona_content": "A researcher who is part of the University of Bristol and has expertise in bone marrow stem cell therapy for the treatment of multiple sclerosis. The researcher has completed a small trial to test the safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. The researcher is hopeful that a larger study may begin recruitment towards the end of this year. The researcher believes that the stem cells mobilised from the marrow to the blood are responsible for improving disease in several ways, including neuroprotection and immune modulation.",
            "persona_id": "221",
            "thought": "As a researcher focused on improving the lives of patients with multiple sclerosis, I value collaboration and equitable outcomes. While the 'Right' option would give me a higher payout personally (1500 vs 1000), it leaves Person A with nothing. The 'Left' option, where both Person A and I receive 1000, seems fairer and aligns better with my values of collaboration and contributing to the greater good. In research, shared success is often more valuable than individual gain. Therefore, I choose the 'Left' option."
        }
    }
}